TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27187992 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Elisa Varrone und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Hemolytic-Uremic Syndrome, Toll-Like Receptor 4. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bologna, Progetto ALICE ONLUS Associazione per la lotta alla SEU, Progetto ALICE ONLUS—Associazione per la lotta alla SEU.
Abstract (Originalsprache)
Childhood infections by Shiga toxin (Stx)-producing Escherichia coli (STEC) cause bloody diarrhea and the life-threatening hemolytic-uremic syndrome (HUS). Stx2, produced by STEC in the gut, is released into the bloodstream and interacts with circulating cells (monocytes, neutrophils, and platelets) through two different receptors: Gb3Cer (globotriaosylceramide) and Toll-like receptor 4 (TLR4). Consequently, blood cells form leukocyte/platelet aggregates and release pathogenic Stx2-containing extracellular vesicles (EVs) that, by damaging the kidney, induce the transition from bloody diarrhea to HUS. Human blood was incubated with Stx2 to induce the formation of neutrophil/platelet and platelet-only aggregates (observed in May–Grünwald Giemsa-stained blood smears) and pathogenic blood cell–derived EVs (isolated by size-exclusion chromatography or differential centrifugation) toxic to Vero cells (assessed by a viability assay). In the presence of a monoclonal antibody against TLR4 (anti-TLR4), the formation of neutrophil/platelet and platelet-only aggregates was greatly reduced compared to treatment with Stx2 alone. Moreover, anti-TLR4 significantly decreased the total mass of pathogenic blood cell–derived EVs produced by Stx2 (detected by nanoparticle tracking analysis), which proved less toxic to Vero cells than those produced by Stx2 alone. The impairment of the Stx2-TLR4 axis obtained during the experimental pathogenesis of HUS provides proof-of-concept evidence supporting TLR4 as a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40126 Bologna, Italy.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Department of Veterinary Medical Sciences (DIMEVET), University of Bologna, Ozzano dell'Emilia, 40064 Bologna, Italy.
ORCID-Profile: Massimiliano Bonafè, Barbara Brunetti, Maurizio Brigotti
Förderung
- University of Bologna
- Progetto ALICE ONLUS Associazione per la lotta alla SEU
- Progetto ALICE ONLUS—Associazione per la lotta alla SEU
Zitieren
APA
Varrone, E., Pepe, V., Storci, G., Bonafè, M., Brunetti, B., & Brigotti, M. (2026). TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27187992
Vancouver
Varrone E, Pepe V, Storci G, Bonafè M, Brunetti B, Brigotti M. TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27187992
BibTeX
@article{Varrone2026,
author = {Varrone, Elisa and Pepe, Veronica and Storci, Gianluca and Bonafè, Massimiliano and Brunetti, Barbara and Brigotti, Maurizio},
title = {TLR4: A Potential Therapeutic Target in the Experimental Pathogenesis of Hemolytic-Uremic Syndrome},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27187992}
}
EUVIMED